Zobrazeno 1 - 10
of 485
pro vyhledávání: '"Nicholas, Chiorazzi"'
Autor:
Ronghua Zhang, Priyanka Khare, Priyanka Banerjee, Cristina Ivan, Sarah Schneider, Federica Barbaglio, Karen Clise-Dwyer, Vanessa Behrana Jensen, Erika Thompson, Marisela Mendoza, Nicholas Chiorazzi, Shih-Shih Chen, Xiao-Jie Joy Yan, Nitin Jain, Paolo Ghia, Federico Caligaris-Cappio, Rima Mendonsa, Sashi Kasimsetty, Ryan Swoboda, Recep Bayraktar, William Wierda, Varsha Gandhi, George A. Calin, Michael J. Keating, Maria Teresa Sabrina Bertilaccio
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract The development and progression of chronic lymphocytic leukemia (CLL) depend on genetic abnormalities and on the immunosuppressive microenvironment. We have explored the possibility that genetic drivers might be responsible for the immune ce
Externí odkaz:
https://doaj.org/article/2643535025b44b18b47bc2931c44d1e2
Autor:
Melanie Schulz, Sanne Bleser, Manouk Groels, Dragan Bošnački, Jan A. Burger, Nicholas Chiorazzi, Carsten Marr
Publikováno v:
iScience, Vol 27, Iss 12, Pp 111242- (2024)
Summary: The Bruton tyrosine kinase inhibitor ibrutinib is an effective treatment for patients with chronic lymphocytic leukemia (CLL). While it rapidly reduces lymph node and spleen size, it initially increases the number of lymphocytes in the blood
Externí odkaz:
https://doaj.org/article/ca44a0f8b44b420d87f0799f6f03ce19
Autor:
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Läubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract The concept of precision cell therapy targeting tumor-specific mutations is appealing but requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of mature lymphoid malignancies are exceptional in that they
Externí odkaz:
https://doaj.org/article/f556d70ecba646069501e54817da7995
Autor:
Kurtis Edwards, Peter M. Lydyard, Nino Kulikova, Tamar Tsertsvadze, Emanuela V. Volpi, Nicholas Chiorazzi, Nino Porakishvili
Publikováno v:
Molecular Medicine, Vol 29, Iss 1, Pp 1-22 (2023)
Abstract Toll-like receptors play a significant role in the innate immune system and are also involved in the pathophysiology of many different diseases. Over the past 35 years, there have been a growing number of publications exploring the role of t
Externí odkaz:
https://doaj.org/article/f06140e300df4a879194db9e189f0eb5
Autor:
Stefano Vergani, Davide Bagnara, Andreas Agathangelidis, Anita Kar Yun Ng, Gerardo Ferrer, Andrea N. Mazzarello, Florencia Palacios, Sophia Yancopoulos, Xiao-Jie Yan, Jaqueline C. Barrientos, Kanti R. Rai, Kostas Stamatopoulos, Nicholas Chiorazzi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe leukemic cells of patients with chronic lymphocytic leukemia (CLL) are often unique, expressing remarkably similar IGHV-IGHD-IGHJ gene rearrangements, “stereotyped BCRs”. The B-cell receptors (BCRs) on CLL cells are also distincti
Externí odkaz:
https://doaj.org/article/13e9226ca5f64baa9b66e56ee46ce5d9
Autor:
Matthew Kaufman, Xiao-Jie Yan, Wentian Li, Emanuela M. Ghia, Anton W. Langerak, Laura Z. Rassenti, Chrysoula Belessi, Neil E. Kay, Frederic Davi, John C. Byrd, Sarka Pospisilova, Jennifer R. Brown, Mark Catherwood, Zadie Davis, David Oscier, Marco Montillo, Livio Trentin, Richard Rosenquist, Paolo Ghia, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Kostas Stamatopoulos, Thomas J. Kipps, Donna Neuberg, Nicholas Chiorazzi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells
Externí odkaz:
https://doaj.org/article/c619ded3a3974ed5becc2e624f138274
Autor:
Byeongho Jung, Gerardo Ferrer, Pui Yan Chiu, Rukhsana Aslam, Anita Ng, Florencia Palacios, Michael Wysota, Martina Cardillo, Jonathan E. Kolitz, Steven L. Allen, Jacqueline C. Barrientos, Kanti R. Rai, Nicholas Chiorazzi, Barbara Sherry
Publikováno v:
JCI Insight, Vol 7, Iss 12 (2022)
Chronic lymphocytic leukemia (CLL) results from expansion of a CD5+ B cell clone that requires interactions with other cell types, including T cells. Moreover, patients with CLL have elevated levels of circulating IL-17A+ and IL-17F+ CD4+ T (Th17) ce
Externí odkaz:
https://doaj.org/article/1c7c156072fb450faf5d7195756c1e4c
Autor:
Pedram Mahmoudi Aliabadi, Ruth Teuber, Peter K. Jani, Landon Wilson, Philipp Enghard, Stephen Barnes, Nicholas Chiorazzi, Andreas Radbruch, Fritz Melchers, Hiromi Kubagawa
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The FcR for IgM (FcµR) is the newest member of the FcR family, selectively expressed by lymphocytes, and distinct from FcRs for switched Ig isotypes that are expressed by various immune cell types and non-hematopoietic cells. From studies of Fcmr-ab
Externí odkaz:
https://doaj.org/article/6f1d02e3cf8f4a39ace658d75146e204
Autor:
Andrea N. Mazzarello, Eva Gentner-Göbel, Marcus Dühren-von Minden, Tatyana N. Tarasenko, Antonella Nicolò, Gerardo Ferrer, Stefano Vergani, Yun Liu, Davide Bagnara, Kanti R. Rai, Jan A. Burger, Peter J. McGuire, Palash C. Maity, Hassan Jumaa, Nicholas Chiorazzi
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 2 (2022)
In chronic lymphocytic leukemia (CLL), the B cell receptor (BCR) plays a critical role in disease development and progression, as indicated by the therapeutic efficacy of drugs blocking BCR signaling. However, the mechanism(s) underlying BCR responsi
Externí odkaz:
https://doaj.org/article/66a5d21ed217411b9bb0675bdc0e82e4
Autor:
Shih-Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Sheila Waters, Jeffery L. Kutok, Marisa Peluso, Sujata Sharma, David T. Weaver, Jonathan A. Pachter, Kanti R. Rai, Nicholas Chiorazzi
Publikováno v:
Clinical Cancer Research. 29:1984-1995
Purpose: Inhibitors of Bruton's tyrosine kinase (BTKi) and PI3K (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. Hence, we sought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e1d04de0e092c271491cfd78719407a
https://doi.org/10.1158/1078-0432.ccr-22-2386
https://doi.org/10.1158/1078-0432.ccr-22-2386